Eagle's Eye View: Your Weekly CV Update From ACC.org

A walkthrough of ORBITA‑2 findings showing PCI may bring greater symptom relief in older adults. A look at the EQUAL trial where Apple smartwatch monitoring raised atrial fibrillation detection rates in older people. A discussion of EMPEROR‑Preserved subgroup data linking baseline magnesium to responses to empagliflozin in heart failure and HFpEF.

They discuss how exercise systolic blood pressure during stress testing links to future cardiovascular events. They review real-world results for the Navitor transcatheter aortic valve, including success and pacemaker rates. They examine 18F-FAPI PET/CT molecular imaging in the right ventricle as a potential risk marker in pulmonary arterial hypertension.

Dr. Eagle dives into the challenges of cardiovascular risk management in the US, highlighting issues like hypertension and diabetes. The impact of semaglutide on hospital admissions is explored, revealing a significant reduction in both hospitalizations and length of stay. Additionally, the ADJUST-DVT study is examined, showcasing how age-adjusted D-dimer testing can enhance diagnostic accuracy for deep vein thrombosis, particularly in older patients. The conversation emphasizes urgent needs in obesity treatment access and the advantages of innovative therapies.

This week’s discussion reveals the link between reduced saturated fat intake and lower mortality risk. A comparison of tirzepatide versus dulaglutide shows no significant differences in cardiovascular events for diabetes patients. Insights from the FINEARTS-HF study highlight hypotension risks associated with finerenone, emphasizing careful monitoring. Additionally, low operator volume in transcatheter procedures is tied to worse outcomes, raising important questions about clinical practice and patient safety.

In this discussion, leading cardiology insights are unpacked, highlighting new guidelines on hypertension, acute coronary syndromes, and congenital heart disease management. Notably, pericarditis guidelines are emphasized as crucial. The podcast explores the role of inflammation in cardiovascular risk and the advancements in anticoagulation treatments. Key articles on SGLT-2 inhibitors and weight management with GLP-1 agents gather attention. Challenges to traditional heart failure practices are questioned, prompting a fresh look at treatment methods.

Dr. Eagle dives into the extended DANISH trial, revealing insights about which patients truly benefit from ICDs. He discusses SURMOUNT-4 findings showing significant weight rebounds after tirzepatide withdrawal, suggesting the need for long-term management strategies. The conversation expands to JACC articles focusing on monitoring transthyretin amyloid cardiomyopathy and assessing cardiovascular risks in oncology patients. Listeners gain practical takeaways from these impactful studies.

Explore the innovative PREVENT equations that enhance cardiovascular risk assessment, integrating kidney and metabolic measures. Delve into the CREST-2 trials, revealing insights on stenting versus endarterectomy for asymptomatic carotid disease. Addressing physician burnout, discover how coaching can make a difference alongside mindfulness practices. Plus, learn about the impact of clear front-of-package food labeling that encourages healthier choices, supported by research on consumer behavior for better cardiovascular health.

Dive into the innovative shift of electrophysiology ablation to outpatient care and its implications for safety and costs. Learn about the alarming rise in heart failure and hypertension rates linked to obesity and diabetes over recent years. Discover critical insights from a new survey on the professional climate for cardiologists, highlighting issues of diversity and mistreatment. Dr. Eagle emphasizes the need for better training and everyday interactions to foster a healthier workplace culture.

Delve into the complexities of gastrointestinal bleeding risks following left atrial appendage occlusion. Discover how lifestyle modifications can effectively treat metabolic syndrome, with evidence showing long-lasting benefits from intensive education. Lastly, explore surprising findings on beta-blockers, revealing their ineffectiveness in reducing mortality and heart issues for patients with preserved left ventricular function. Tune in for crucial insights into cardiovascular care!

Delve into groundbreaking research presented at the recent American Heart Association Scientific Sessions. Discover the OCEAN Trial's insights on antithrombotic strategies for atrial fibrillation. Learn about the VESALIUS-CV study, showcasing evolocumab's effectiveness in reducing major cardiovascular events. Finally, explore POLY-HF, which introduces a revolutionary polypill that enhances heart function and quality of life in patients with heart failure. Transformative findings are paving the way for improved cardiac care!